Envista Holdings (NVST) Research & Development (2018 - 2026)
Envista Holdings (NVST) posted quarterly Research & Development of $30.0 million for Q2 2026, up 18.58% year-over-year from $25.3 million in Q2 2025, and down 6.54% quarter-over-quarter from $32.1 million in Q4 2025.
Envista Holdings (NVST) Research & Development (2018 - 2026) Analysis & Trends
Envista Holdings' Research & Development history runs 9 years deep, the most recent figure standing at $30.0 million for Q2 2026.
- In Q2 2026, Research & Development rose 18.58% year-over-year to $30.0 million; the TTM figure through Apr 2026 stood at $118.7 million (up 17.41% YoY), while the FY2025 annual figure was $114.0 million, up 15.04% from the prior year.
- Research & Development for Q2 2026 stood at $30.0 million, down from $32.1 million in the prior quarter.
- The five-year high for Research & Development was $32.1 million in Q4 2025, with the low at $20.2 million in Q4 2023.
- The 5-year median for Research & Development is $25.3 million (2025), against an average of $25.7 million.
- The sharpest annual moves came in 2023 and 2024: Research & Development retreated 17.89% in 2023, then surged 32.18% in 2024.
- Envista Holdings' Research & Development stood at $24.6 million in 2022, then dropped by 17.89% to $20.2 million in 2023, then surged by 32.18% to $26.7 million in 2024, then climbed by 20.22% to $32.1 million in 2025, then decreased by 6.54% to $30.0 million in 2026.
- Business Quant data shows NVST's Research & Development at $30.0 million in Q2 2026, $32.1 million in Q4 2025, and $28.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.71 Bn | 127.50 Bn | 1.96 Bn | 370.60 Mn |
| 2 | Becton Dickinson | 51.57 Bn | 50.71 Bn | 2.32 Bn | 258.00 Mn |
| 3 | Alcon | 35.52 Bn | 34.17 Bn | 1.68 Bn | 663.00 Mn |
| 4 | Resmed | 33.28 Bn | 31.81 Bn | 861.22 Mn | 105.73 Mn |
| 5 | Medline | 27.86 Bn | 25.18 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.15 Bn | 24.71 Bn | 329.20 Mn | 19.70 Mn |
| 7 | Solventum | 15.31 Bn | 14.91 Bn | 1.29 Bn | 178.00 Mn |
| 8 | Cooper Companies | 14.86 Bn | 14.72 Bn | 735.40 Mn | 42.50 Mn |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 129.00 Mn |
| 10 | Envista Holdings | 4.37 Bn | 3.24 Bn | 407.00 Mn | 30.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 30.40 Mn |
| Apr 3, 2026 | 30.00 Mn |
| Dec 31, 2025 | 32.10 Mn |
| Sep 26, 2025 | 28.30 Mn |
| Jun 27, 2025 | 28.30 Mn |
| Mar 28, 2025 | 25.30 Mn |
| Dec 31, 2024 | 26.70 Mn |
| Sep 27, 2024 | 25.50 Mn |
| Jun 28, 2024 | 23.60 Mn |
| Mar 29, 2024 | 23.30 Mn |
| Dec 31, 2023 | 20.20 Mn |
| Sep 29, 2023 | 22.30 Mn |
| Jun 30, 2023 | 26.80 Mn |
| Mar 31, 2023 | 24.50 Mn |
| Dec 31, 2022 | 24.60 Mn |
| Sep 30, 2022 | 26.00 Mn |
| Jul 1, 2022 | 25.10 Mn |
| Apr 1, 2022 | 24.40 Mn |
| Dec 31, 2021 | 24.80 Mn |
| Oct 1, 2021 | 24.00 Mn |